|
1
|
American Cancer Society: Cancer Facts
& Figures 1994. American Cancer Society. Atlanta, GA:
131994.
|
|
2
|
Kumar S, Pathania AS, Saxena AK, et al:
The anticancer potential of flavonoids isolated from the stem bark
of Erythrina suberosa through induction of apoptosis and
inhibition of STAT signaling pathway in human leukemia HL-60 cells.
Chem Biol Interact. 205:128–137. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baselga J and Swain SM: Novel anticancer
targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Beliakoff J and Whitesell L: Hsp90: an
emerging target for breast cancer therapy. Anticancer Drugs.
15:651–662. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mendelsohn J and Baselga J: Epidermal
growth factor receptor targeting in cancer. Semin Oncol.
33:369–385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Solit DB and Chiosis G: Development and
application of Hsp90 inhibitors. Drug Discov Today. 13:38–43. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mendelsohn J and Baselga J: Status of
epidermal growth factor receptor antagonists in the biology and
treatment of cancer. J Clin Oncol. 21:2787–2799. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Citri A, Kochupurakkal BS and Yarden Y:
The Achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone
machine and potential for pharmacological intervention. Cell Cycle.
3:51–60. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taldone T, Sun W and Chiosis G: Discovery
and development of heat shock protein 90 inhibitors. Bioorg Med
Chem. 17:2225–2235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Whitesell L and Lindquist SL: HSP90 and
the chaperoning of cancer. Nat Rev Cancer. 5:761–772. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pick E, Kluger Y, Giltnane JM, et al: High
HSP90 expression is associated with decreased survival in breast
cancer. Cancer Res. 67:2932–2937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song CH, Park SY, Eom KY, et al: Potential
prognostic value of heat-shock protein 90 in the presence of
phosphatidylinositol-3-kinase overexpression or loss of PTEN, in
invasive breast cancers. Breast Cancer Res. 12:R202010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smith-Jones PM, Solit D, Afroze F, Rosen N
and Larson SM: Early tumor response to Hsp90 therapy using HER2
PET: comparison with 18F-FDG PET. J Nucl Med. 47:793–796.
2006.PubMed/NCBI
|
|
15
|
Costantini DL, Bateman K, McLarty K, et
al: Trastuzumab-resistant breast cancer cells remain sensitive to
the Auger electron-emitting radiotherapeutic agent
111In-NLS-trastuzumab and are radiosensitized by methotrexate. J
Nucl Med. 49:1498–1505. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Orlova A, Wållberg H, Stone-Elander S and
Tolmachev V: On the selection of a tracer for PET imaging of
HER2-expressing tumors: direct comparison of a 124I-labeled
affibody molecule and trastuzumab in murine xenograft model. J Nucl
Med. 50:417–425. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kramer-Marek G, Kiesewetter DO and Capala
J: Changes in HER2 expression in breast cancer xenografts after
therapy can be quantified using PET and (18)F-labeled affibody
molecules. J Nucl Med. 50:1131–1139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dijkers EC, Kosterink JG, Rademaker AP, et
al: Development and characterization of clinical-grade
89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med.
50:974–981. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Newman DJ and Cragg GM: Natural products
as sources of new drugs over the 30 years from 1981 to 2010. J Nat
Prod. 75:311–335. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hargreaves RT, Jonson RD, Millington DS,
et al: Alkaloids of American species of Erythrina. Lloydia.
37:569–580. 1974.PubMed/NCBI
|
|
21
|
Chopra RN, Nayar SL and Chopra IC:
Glossary of Indian Medicinal Plants. CSIR. New Delhi: 1956.
|
|
22
|
Garín-Aguilar ME, Luna JE, Soto-Hernández
M, et al: Effect of crude extracts of Erythrina americana
Mill. on aggressive behavior in rats. J Ethnopharmacol. 69:189–196.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Agrawal SK, Agrawal M, Sharma PR, et al:
Induction of apoptosis in human promyelocytic leukemia HL60 cells
by an extract from Erythrina suberosa stem bark. Nutr
Cancer. 63:802–813. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gallegos Ruiz MI, Floor K, Roepman P,
Rodriguez JA, et al: Integration of gene dosage and gene expression
in non-small cell lung cancer, identification of HSP90 as potential
target. PLoS One. 3:e00017222008.PubMed/NCBI
|
|
25
|
Garcia-Carbonero R, Carnero A and Paz-Ares
L: Inhibition of HSP90 molecular chaperones: moving into the
clinic. Lancet Oncol. 14:e358–e369. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pick E, Kluger Y, Giltnane JM, Moeder C,
Camp RL, Rimm DL and Kluger HM: High HSP90 expression is associated
with decreased survival in breast cancer. Cancer Res. 67:2932–2937.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ciocca DR, Clark GM, Tandon AK, Fuqua SA,
Welch WJ and McGuire WL: Heat shock protein hsp70 in patients with
axillary lymph node-negative breast cancer: prognostic
implications. J Natl Cancer Inst. 85:570–574. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim LS and Kim JH: Heat shock protein as
molecular target for breast cancer therapeutics. J Breast Cancer.
14:167–174. 2011. View Article : Google Scholar : PubMed/NCBI
|
